The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00090116
- Lead Sponsor
- Forest Laboratories
- Brief Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 400
- Clinical diagnosis of moderate to severe Alzheimer's disease;
- ambulatory patients
- folate deficiency;
- clinically significant central nervous system disease other than Alzheimer's disease;
- clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (34)
Ohio State University
🇺🇸Columbus, Ohio, United States
UCI Medical Center
🇺🇸Orange, California, United States
Piedmont Medical Research
🇺🇸Winston Salem, North Carolina, United States
Indiana Universisty Medical Center
🇺🇸Indianapolis, Indiana, United States
Pivotal Research Centers
🇺🇸Peoria, Arizona, United States
Alzheimer's Research Corporation
🇺🇸Lakehurst, New Jersey, United States
Berma Research Group
🇺🇸Hialeah, Florida, United States
Margolin Brain Institute
🇺🇸Fresno, California, United States
Palm Beach Neurology
🇺🇸West Palm Beach, Florida, United States
Pharmacology Research Institute
🇺🇸Northridge, California, United States
Palm Beach Neurological Center
🇺🇸Palm Beach Gardens, Florida, United States
Ubhc/Umdnj
🇺🇸Piscataway, New Jersey, United States
Neurology and Neuroscience Center of Ohio
🇺🇸Toledo, Ohio, United States
Mood and Memory Clinic of Michigan
🇺🇸Farmington Hills,, Michigan, United States
21st Century Neurology
🇺🇸Phoenix, Arizona, United States
Pacific Research Network
🇺🇸San Diego, California, United States
Affiliated Research Institute
🇺🇸San Diego, California, United States
Nathan S. Kline Institute for Psychiatric Research
🇺🇸Orangeburg, New York, United States
Monroe Community Hospital
🇺🇸Rochester, New York, United States
Pioneer Pharmaceutical Research
🇺🇸Midvale, Utah, United States
J. Gary Booker, MD
🇺🇸Shreveport, Louisiana, United States
Upstate Clinical Research
🇺🇸Albany, New York, United States
Neurology Clinical Research, Inc.
🇺🇸Plantation, Florida, United States
Behavioral Medical Research of Saten Island, PC
🇺🇸Staten Island, New York, United States
St. Louis University
🇺🇸St. Louis, Missouri, United States
North Texas Neurology Research
🇺🇸Wichita, Texas, United States
Baumel-Eisner Neuromedical Institute
🇺🇸Ft. Lauderdale, Florida, United States
Joel Ross, MD
🇺🇸Long Branch, New Jersey, United States
University of South Florida
🇺🇸Tampa, Florida, United States
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
Lexington Clinic
🇺🇸Lexington, Kentucky, United States
Summit Research Network
🇺🇸Portland, Oregon, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States